Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Topography of Regional Cerebral GABA<sub>A</sub> Receptor Availability in Parkinson's Disease Patients With Freezing of Gait.

The European journal of neuroscience·2026
Same author

Excessive GABAergic activity in striatal and frontal cortical regions more than dopaminergic functions are related to daytime sleepiness in Parkinson's disease: An exploratory 11C-flumazenil PET study.

Geromedicine·2026
Same author

Cholinergic system changes in levodopa-unresponsive freezing of gait and failure of goal-directed motor behavior in Parkinson's disease.

Neural regeneration research·2026
Same author

White matter lesions disrupt cholinergic pathways important for cognition in Parkinson's disease.

Brain : a journal of neurology·2026
Same author

Asymmetric Cholinergic Basal Forebrain Atrophy Marks Freezing of Gait in Parkinson's Disease.

The European journal of neuroscience·2026
Same author

Baseline Regional Cholinergic Denervation Predicts Cognitive Trajectories in Moderate Parkinson Disease.

Annals of clinical and translational neurology·2026
Same journal

The Noradrenergic Brain in Parkinson's Disease.

Current neurology and neuroscience reports·2026
Same journal

Mapping the Silent Onset of Parkinson's Disease: Monoamine Imaging in the Era of the Race for Preclinical Intervention.

Current neurology and neuroscience reports·2026
Same journal

Functional and Structural Brain Imaging Correlates of Treatment Response in Functional Movement Disorder.

Current neurology and neuroscience reports·2026
Same journal

Astrocytopathy in Wernicke Encephalopathy and Neuromyelitis Optica Spectrum Disorder. Pathogenic Differences With Occasional Clinical and Neuroimaging Overlap. A Review.

Current neurology and neuroscience reports·2026
Same journal

When is the Radiologically Isolated Syndrome already Multiple Sclerosis According to the 2024 McDonald Criteria?

Current neurology and neuroscience reports·2026
Same journal

Assessment and Management of Post-traumatic Headache.

Current neurology and neuroscience reports·2026
See all related articles

Related Experiment Video

Updated: May 8, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Cholinergic dysfunction in Parkinson's disease.

Martijn L T M Müller1, Nicolaas I Bohnen

  • 1Functional Neuroimaging, Cognitive, and Mobility Laboratory, Department of Radiology, Division of Nuclear Medicine, University of Michigan, 24 Frank Lloyd Wright Dr, Box #362, Ann Arbor, MI 48105, USA. mtmuller@med.umich.edu

Current Neurology and Neuroscience Reports
|August 15, 2013
PubMed
Summary
This summary is machine-generated.

Degeneration of the cholinergic system, including the pedunculopontine complex (PPN), significantly impacts Parkinson's disease (PD) motor symptoms and falls. This highlights the PPN's role in dopamine-resistant mobility issues.

More Related Videos

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Related Experiment Videos

Last Updated: May 8, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Area of Science:

  • Neuroscience
  • Neurology
  • Movement Disorders

Background:

  • Parkinson's disease (PD) is primarily associated with dopaminergic neuron loss.
  • Emerging evidence implicates cholinergic system degeneration, particularly in the basal forebrain and pedunculopontine complex (PPN), in PD pathophysiology.
  • The clinical significance of cholinergic denervation in PD, beyond cognitive decline, is increasingly recognized.

Purpose of the Study:

  • To investigate the role of cholinergic basal forebrain and PPN degeneration in the diverse clinical manifestations of Parkinson's disease.
  • To explore the association between cholinergic integrity and motor impairments, including falling and reduced walking speed.
  • To establish a new framework for understanding dopamine-resistant motor symptoms in PD.

Main Methods:

  • Review of recent evidence on cholinergic system degeneration in PD.
  • Analysis of in vivo imaging and human post-mortem data linking PPN integrity to falling.
  • Examination of primate brainstem lesioning studies on PPN and mobility.
  • Correlation of basal forebrain cholinergic degeneration with walking speed.

Main Results:

  • Cholinergic denervation in PD is variable and may contribute to symptom heterogeneity.
  • Impaired cholinergic integrity of the PPN is associated with frequent falling in PD.
  • PPN lesions in primates cause mobility impairment.
  • Basal forebrain cholinergic degeneration correlates with decreased walking speed in PD patients.

Conclusions:

  • Cholinergic system degeneration, especially in the PPN, plays a critical role in dopamine-resistant mobility impairments in Parkinson's disease.
  • These findings suggest a new paradigm for understanding and potentially treating motor deficits in PD.
  • Further research into cholinergic therapies for PD symptoms is warranted.